Psychose-Risiko
Studienlage · Detail Meta-Analyse · Psychose-Risiko · 2026

Prevalence of schizophrenia spectrum and bipolar disorder among patients with cannabis induced psychosis: a systematic review and meta-analysis.

Unklar GRADE Hoch 0 Zitate
Stichprobek = 13 Studien
n = 7.515 Pat.
Dauerunklar
EndpunktPrävalenz…
Verblindungunklar
DesignMeta-Analyse
Kernaussage

Meta-Analyse zur Prävalenz von Schizophrenie-Spektrum (20%) und bipolaren Störungen (5%) nach cannabisinduzierter Psychose; keine Interventionsbewertung.

Zusammenfassung

Systematische Review + Meta-Analyse über k=13 Studien (n=7.515) zu Cannabis-induzierter Psychose und Folge-Diagnosen. 20% (95% CI: 15,8–29,5%) entwickelten später Schizophrenie-Spektrum-Störung, 5% (95% CI: 2,7–6,9%) Bipolare Störung, 63% (95% CI: 26,8–90,5%) unspezifizierte Diagnose. Patienten hatten 76% geringeres Risiko für Bipolare Störung vs. Schizophrenie-Spektrum; unspezifizierte Diagnose zeigte ARR=2,52 (95% CI: 1,03–6,15) vs. Schizophrenie-Spektrum allein.

P
PopulationPatienten mit Cannabis-induzierter Psychose, gepoolte n=7.515
I
InterventionCannabis-induzierte Psychose (als Exposition/Ausgangsbefund)
O
OutcomeGepoolte Prävalenz: 20% (95% CI: 15,8–29,5%) entwickelten später eine Schizophrenie-Spektrum-Störung; 5% (95% CI: 2,7–6,9%) eine bipolare Störung; 63% (95% CI: 26,8–90,5%) eine unspezifizierte Störung; Risiko für bipolare Störung 76% geringer als für Schizophrenie-Spektrum
Vertrauen in die Evidenz
Hoch

Höchste von vier GRADE-Stufen, die Effektschätzung ist sehr verlässlich.

Qualitätsprofil
Größe
Verblindung
Effektstärke
Zitate / Jahr
Autoren
Javed MS, El-Khoury R, Taha AA, Reagu SM
DOI 10.1186/s12888-025-07382-2
Design: Meta-Analyse
Teilen
Abstract
Background: Distinguishing cannabis-induced psychosis from primary psychiatric disorders is difficult and has significant clinical and prognostic implications. Current treatment approaches lack standardized guidelines, potentially leading to the development of schizophrenia spectrum and bipolar disorder. This study systematically reviews the literature and provides a pooled prevalence of later developing these disorders following a cannabis-induced psychosis diagnosis. Methods: We systematically reviewed Medline, Embase, Web of Science, Google Scholar, and PsychInfo for studies reporting on a group of patients with cannabis-induced psychosis and subsequent diagnoses of schizophrenia spectrum disorder, bipolar disorder, or both. The search was conducted until January 1, 2025. A modified version of the Newcastle-Ottawa scale was used to assess study quality. Random-effects meta-analyses were conducted to calculate pooled mean prevalence. Random-effects meta-regressions were used to identify predictors of higher prevalence. Results: Our strategy identified 13 studies eligible for inclusion with a total population size of 7,515 which reported a total of 16 outcomes of interest. Among cannabis induced psychosis patients, 20% (95% CI:15.8-29.5%) later received a schizophrenia spectrum diagnosis, 5% (95% CI:2.7-6.9%) bipolar and 63% (95% CI:26.8-90.5%) unspecified (both). Compared to individuals receiving a later schizophrenia spectrum disorder diagnosis, patients were 76% less likely to develop bipolar disorder. Later diagnosis of an unspecified disorder showed an approximate 3 folds higher risk with an ARR of 2.52 (95% CI: 1.03-6.15) compared to schizophrenia spectrum disorder alone. Conclusions: Approximately one in five patients diagnosed with cannabis-induced psychosis will develop schizophrenia spectrum disorder, while one in twenty will be later diagnosed with bipolar disorder.

„Was dem Handeln im Weg steht, wird zum Weg.“ — Marc Aurel